Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion NV to Present Further Preclinical Data at 2019 ARVO Meeting

26 Apr 2019

Leuven, Belgium, 26 April 2019 Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease,announced today two podium presentations and a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held April 28  – May 2, 2019 in Vancouver at the Vancouver Convention Centre.

The podium presentation "The effect of combined PlGF and VEGF inhibition on vascular leakage and inflammation in experimental murine models" will be delivered Sunday, April 28 at 3.45 - 4.00 p.m. PDT.

The poster “Placental growth factor (PlGF) induced signalling regulates barrier properties of the retinal pigment epithelium (RPE)” will be presented Monday, April 29 at 11.15 a.m. - 1.00 p.m. PDT.

The podium presentation "A potential role for Src during early experimental diabetic retinopathy?" will be delivered on Tuesday, April 30 at 8.45 - 9.00 a.m. PDT.

Press release attachment: